Aberdeen Group
CRBP icon

Aberdeen Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Aberdeen Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.4M Hold
1,321,750
– – 0.02% 561
2026
Q1 		$12.4M Hold
1,321,750
– – 0.02% 548
2025
Q4 		$10.8M Buy
1,321,750
+1,133,519
+602% +$14M 0.02% 595
2025
Q3 		$2.38M Buy
188,231
+116,005
+161% +$1.1M ﹤0.01% 765
2025
Q2 		$498K Buy
72,226
+45,332
+169% +$329K ﹤0.01% 884
2025
Q1 		$143K Hold
26,894
– – ﹤0.01% 932
2024
Q4 		$317K Hold
26,894
– – ﹤0.01% 892
2024
Q3 		$555K Buy
26,894
+21,751
+423% +$1.11M ﹤0.01% 850
2024
Q2 		$233K Hold
5,143
– – ﹤0.01% 917
2024
Q1 		$202K Buy
+5,143
New +$127K ﹤0.01% 929

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Aberdeen Group's CRBP Position: Q2 2026 in Review

Aberdeen Group held its Corbus Pharmaceuticals (CRBP) position steady in Q2 2026 at 1,321,750 shares worth $12.4M. The position accounts for 0.02% of the portfolio, ranked #561.

Aberdeen Group first reported a position in CRBP in Q1 2024 and has held it in 10 quarters since. The position peaked at $12.4M in Q1 2026. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Aberdeen Group held 1,321,750 shares of Corbus Pharmaceuticals worth $12.4M as of Q2 2026.
  • Aberdeen Group left its Corbus Pharmaceuticals share count unchanged in Q2 2026.
  • Corbus Pharmaceuticals made up 0.02% of Aberdeen Group's portfolio in Q2 2026, its #561 holding.
  • Aberdeen Group first reported a position in Corbus Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Aberdeen Group's Corbus Pharmaceuticals position peaked at $12.4M in Q1 2026.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.